Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33


Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

Circulation. 2009 Apr 21;119(15):2069-77. doi: 10.1161/CIRCULATIONAHA.108.803916. Epub 2009 Apr 6.


The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.

McGuire DK, See R, Abdullah SM, Snell PG, McGavock JM, Ayers CR, Szczepaniak LS.

Diab Vasc Dis Res. 2009 Jan;6(1):43-50. doi: 10.3132/dvdr.2009.009.


Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators..

JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31.


New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.

McGuire DK, Inzucchi SE.

Circulation. 2008 Jan 22;117(3):440-9. doi: 10.1161/CIRCULATIONAHA.107.704080. Review. No abstract available.


.VO2max: what do we know, and what do we still need to know?

Levine BD.

J Physiol. 2008 Jan 1;586(1):25-34. Epub 2007 Nov 15. Review.


Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group..

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.


A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP.

J Am Coll Cardiol. 2007 Apr 24;49(16):1696-704. Epub 2007 Apr 6.


Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM.

JAMA. 2006 Dec 6;296(21):2572-81. Epub 2006 Nov 13.


Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G; Rosiglitazone Fluid Retention Study Group..

J Am Soc Nephrol. 2006 Dec;17(12):3482-90. Epub 2006 Nov 8.


Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.

Regensteiner JG, Bauer TA, Reusch JE.

Diabetes Care. 2005 Dec;28(12):2877-83.


Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

Patel C, Wyne KL, McGuire DK.

Diab Vasc Dis Res. 2005 May;2(2):61-6. Review.


Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators..

Lancet. 2005 Oct 8;366(9493):1279-89.


Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD.

Nat Med. 2005 Aug;11(8):861-6. Epub 2005 Jul 10.


Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T.

Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9406-11. Epub 2005 Jun 14.


Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography.

Hoffmann R, von Bardeleben S, ten Cate F, Borges AC, Kasprzak J, Firschke C, Lafitte S, Al-Saadi N, Kuntz-Hehner S, Engelhardt M, Becher H, Vanoverschelde JL.

Eur Heart J. 2005 Mar;26(6):607-16. Epub 2004 Dec 17.


Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R; American Heart Association.; American Diabetes Association..

Circulation. 2003 Dec 9;108(23):2941-8. Review. No abstract available.


Aerobic work capacity in men and women with special reference to age.


Acta Physiol Scand Suppl. 1960;49(169):1-92. No abstract available.


Metformin and thiazolidinedione use in Medicare patients with heart failure.

Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM.

JAMA. 2003 Jul 2;290(1):81-5.


Supplemental Content

Support Center